| Identification | Back Directory | [Name]
SM 6586 | [CAS]
103898-38-0 | [Synonyms]
SM 6586
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-[3-[[methyl(phenylmethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-nitrophenyl)-, methyl ester | [Molecular Formula]
C26H27N5O5 | [MDL Number]
MFCD00870321 | [MOL File]
103898-38-0.mol | [Molecular Weight]
489.52 |
| Chemical Properties | Back Directory | [Melting point ]
127-128 °C | [Boiling point ]
624.0±65.0 °C(Predicted) | [density ]
1.270±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
5.10±0.50(Predicted) |
| Hazard Information | Back Directory | [Uses]
SM-6586 is a calcium channel antagonist and inhibitor of Na+/H+ and Na+/Ca2+ exchange transport, potentially for the treatment of cerebrovasular diseases and hypertension. | [in vivo]
In SM-6586-treated spontaneously hypertensive rats, the survival rate after bilateral common carotid artery ligation is higher, the brain water content is lower, and the ATP level is higher and lactate level. In focal ischemia models, the SM-treated group shows a reduction of T1 relaxation time. The brain water content is significantly decreased in the SM-treated group[1]. | [storage]
Store at -20°C | [References]
[1] Kashiwagi F, et al. Effect of a new calcium antagonist (SM-6586) on experimental cerebral ischemia. Acta Neurochir Suppl (Wien). 1994;60:289-92. DOI:10.1007/978-3-7091-9334-1_77 |
|
|